NO2324360T3 - - Google Patents
Info
- Publication number
- NO2324360T3 NO2324360T3 NO09807153A NO09807153A NO2324360T3 NO 2324360 T3 NO2324360 T3 NO 2324360T3 NO 09807153 A NO09807153 A NO 09807153A NO 09807153 A NO09807153 A NO 09807153A NO 2324360 T3 NO2324360 T3 NO 2324360T3
- Authority
- NO
- Norway
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
- A61B5/4064—Evaluating the brain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18855408P | 2008-08-11 | 2008-08-11 | |
US9762208P | 2008-09-17 | 2008-09-17 | |
US21872709P | 2009-06-19 | 2009-06-19 | |
PCT/US2009/053376 WO2010019553A2 (en) | 2008-08-11 | 2009-08-11 | Biomarker detection process and assay of neurological condition |
Publications (1)
Publication Number | Publication Date |
---|---|
NO2324360T3 true NO2324360T3 (ja) | 2018-06-30 |
Family
ID=41669607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO09807153A NO2324360T3 (ja) | 2008-08-11 | 2009-08-11 |
Country Status (9)
Country | Link |
---|---|
US (3) | US20110143375A1 (ja) |
EP (3) | EP4235181A3 (ja) |
JP (2) | JP5781436B2 (ja) |
AU (1) | AU2009282117B2 (ja) |
CA (1) | CA2733990C (ja) |
DK (1) | DK2324360T3 (ja) |
ES (1) | ES2665245T3 (ja) |
NO (1) | NO2324360T3 (ja) |
WO (1) | WO2010019553A2 (ja) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1519194A1 (en) | 2003-09-24 | 2005-03-30 | Roche Diagnostics GmbH | Use of gfap for identification of intracerebral hemorrhage |
US8492107B2 (en) | 2004-04-15 | 2013-07-23 | University Of Florida Research Foundation, Inc. | Neural proteins as biomarkers for nervous system injury and other neural disorders |
SG10201704689XA (en) | 2008-01-18 | 2017-07-28 | Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
EP4235181A3 (en) * | 2008-08-11 | 2024-02-28 | Banyan Biomarkers Inc | Biomarker detection process and assay of neurological condition |
EP3355059A3 (en) * | 2009-06-19 | 2018-09-26 | Banyan Biomarkers, Inc. | Biomarker assay of neurological condition |
WO2011011334A2 (en) * | 2009-07-18 | 2011-01-27 | Banyan Biomarkers, Inc. | SYNERGISTIC BIOMARKER ASSAY OF NEUROLGICAL CONDITION USING S-100β |
JP5909447B2 (ja) * | 2009-09-14 | 2016-04-26 | バンヤン・バイオマーカーズ・インコーポレーテッド | ニューロン損傷診断のためのマイクロrna、自己抗体およびタンパク質マーカー |
EP2531224B1 (en) | 2010-01-26 | 2019-06-05 | Bioregency, Inc. | Compositions and methods relating to argininosuccinate synthetase |
AU2011235892B2 (en) * | 2010-04-01 | 2016-07-07 | Banyan Biomarkers, Inc. | Markers and assays for detection of neurotoxicity |
WO2011160096A2 (en) * | 2010-06-17 | 2011-12-22 | Banyan Biomarkers, Inc. | Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition |
MX361944B (es) | 2010-07-23 | 2018-12-19 | President And Fellows Of Harvard College Star | Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales. |
US20130203624A1 (en) | 2010-07-23 | 2013-08-08 | President And Fellows Of Harvard College | Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions |
AU2011280997A1 (en) | 2010-07-23 | 2013-02-28 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
JP2013541323A (ja) | 2010-07-23 | 2013-11-14 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 貪食細胞を用いて疾患または症状のシグネチャを検出する方法 |
WO2012051519A2 (en) * | 2010-10-14 | 2012-04-19 | The Johns Hopkins University | Biomarkers of brain injury |
WO2012142301A2 (en) | 2011-04-12 | 2012-10-18 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury |
JP2014518624A (ja) | 2011-05-12 | 2014-08-07 | ザ・ジョンズ・ホプキンス・ユニバーシティー | ニューログラニン診断キットのためのアッセイ試薬 |
WO2013090285A1 (en) * | 2011-12-14 | 2013-06-20 | University Of Rochester | Method of diagnosing mild traumatic brain injury |
WO2013138509A1 (en) | 2012-03-13 | 2013-09-19 | The Johns Hopkins University | Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration |
KR20150035821A (ko) | 2012-06-15 | 2015-04-07 | 해리 스타일리 | 질환 또는 병태를 검출하는 방법 |
KR20150035818A (ko) | 2012-06-15 | 2015-04-07 | 해리 스타일리 | 순환 병든 세포를 사용하여 질환 또는 병태를 검출하는 방법 |
US11585814B2 (en) | 2013-03-09 | 2023-02-21 | Immunis.Ai, Inc. | Methods of detecting prostate cancer |
US10494675B2 (en) | 2013-03-09 | 2019-12-03 | Cell Mdx, Llc | Methods of detecting cancer |
WO2014144133A1 (en) * | 2013-03-15 | 2014-09-18 | The Trustees Of The Princeton University | Analyte detection enhancement by targeted immobilization, surface amplification, and pixelated reading and analysis |
US20150141528A1 (en) * | 2013-05-31 | 2015-05-21 | Banyan Biomarkers, Inc. | Neural specific s100b for biomarker assays and devices for detection of a neurological condition |
US10534003B2 (en) * | 2013-07-17 | 2020-01-14 | The Johns Hopkins University | Multi-protein biomarker assay for brain injury detection and outcome |
CN106605146B (zh) * | 2014-04-08 | 2020-07-28 | 佛罗里达大学研究基金会有限公司 | 用于中枢神经系统的急性、亚急性和慢性创伤性损伤的蛋白质标志物 |
WO2016040843A1 (en) | 2014-09-11 | 2016-03-17 | Harry Stylli | Methods of detecting prostate cancer |
WO2016055148A2 (en) * | 2014-10-06 | 2016-04-14 | Université De Genève | Markers and their use in brain injury |
US20190010504A1 (en) * | 2015-12-11 | 2019-01-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Human alzheimer's disease and traumatic brain injury associated tau variants as biomarkers and methods of use thereof |
BR112019006710A2 (pt) * | 2016-10-03 | 2019-06-25 | Abbott Lab | métodos aprimorados para avaliação do estado da uch-l1 em amostras de pacientes |
EP3532496A1 (en) | 2016-10-28 | 2019-09-04 | Banyan Biomarkers, Inc. | Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods |
US10345302B2 (en) * | 2017-02-19 | 2019-07-09 | Sheng-He Huang | Circulating astrocytes and MFSD2A as biomarkers |
US11016092B2 (en) | 2017-03-23 | 2021-05-25 | Abbott Laboratories | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1 |
EP3602069A1 (en) * | 2017-03-23 | 2020-02-05 | Abbott Laboratories | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1 |
WO2018191531A1 (en) | 2017-04-15 | 2018-10-18 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers |
BR112019022476A2 (pt) | 2017-04-28 | 2020-05-12 | Abbott Laboratories | Métodos para o auxílio no diagnóstico e determinação hiperagudos de lesão cerebral traumática usando biomarcadores iniciais em pelo menos duas amostras a partir do mesmo ser humano |
CA3078725A1 (en) * | 2017-05-25 | 2018-11-29 | Abbott Laboratories | Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers |
BR112019025313A2 (pt) * | 2017-05-30 | 2020-06-23 | Abbott Laboratories | Métodos para auxílio no diagnóstico e avaliação de uma lesão cerebral traumática leve em um indivíduo humano usando troponina cardíaca i |
EP3649474A1 (en) | 2017-07-03 | 2020-05-13 | Abbott Laboratories | Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood |
WO2019018545A1 (en) | 2017-07-18 | 2019-01-24 | The Research Foundation For The State University Of New York | BIOMARKERS OF INTRACRANIAL ANEVISM |
US11016105B2 (en) | 2017-12-09 | 2021-05-25 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1 |
EP3721233A2 (en) * | 2017-12-09 | 2020-10-14 | Abbott Laboratories | Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1) |
WO2019199871A1 (en) * | 2018-04-10 | 2019-10-17 | Quanterix Corporation | Quantification of neurofilament light chain in physiological samples |
KR102179032B1 (ko) * | 2019-09-20 | 2020-11-18 | 한림대학교 산학협력단 | 급성허혈성뇌손상 및 급성외상성뇌손상을 구별하기 위한 바이오마커 및 이의 이용 |
JP2023551542A (ja) | 2020-11-30 | 2023-12-08 | エニグマ バイオインテリジェンス,インコーポレイテッド | アルツハイマー病の非侵襲的評価 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5234814A (en) * | 1989-06-01 | 1993-08-10 | Du Pont Merck Pharmaceutical Company | Diagnostic assay for alzheimer's disease |
US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
US5707796A (en) * | 1990-06-11 | 1998-01-13 | Nexstar Pharmaceuticals, Inc. | Method for selecting nucleic acids on the basis of structure |
US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
ES2259800T3 (es) | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
US5683867A (en) | 1990-06-11 | 1997-11-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: blended SELEX |
US5252463A (en) * | 1990-06-22 | 1993-10-12 | The Du Pont Merck Pharmaceutical Company | Clipsin, a chymotrypsin-like protease and method of using same |
US5536639A (en) * | 1994-03-25 | 1996-07-16 | Cephalon, Inc. | Methods for detecting calpain activation by detection of calpain activated spectrin breakdown products |
ATE268816T1 (de) * | 1994-07-15 | 2004-06-15 | Cephalon Inc | In baculovirus exprimiertes aktives calpain |
US5614649A (en) * | 1994-11-14 | 1997-03-25 | Cephalon, Inc. | Multicatalytic protease inhibitors |
US5777194A (en) * | 1995-04-26 | 1998-07-07 | Cephalon, Inc. | Gene-targeted mice with humanized Aβ sequence and Swedish FAD mutation |
US6048703A (en) * | 1996-11-15 | 2000-04-11 | Cephalon, Inc. | Methods for detecting cell apoptosis |
US6218005B1 (en) * | 1999-04-01 | 2001-04-17 | 3M Innovative Properties Company | Tapes for heat sealing substrates |
US6664442B2 (en) * | 2000-03-30 | 2003-12-16 | Elan Pharmaceuticals, Inc. | Selecting compounds to reduce inflammation associated with Alzheimer's disease |
WO2003016910A1 (en) * | 2001-08-20 | 2003-02-27 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
AU2002329570A1 (en) * | 2001-10-12 | 2003-01-30 | Pfizer Products Inc. | Method of monitoring neuroprotective treatment |
WO2004025298A1 (en) * | 2002-09-11 | 2004-03-25 | University Of Florida | Analyzing nerve cell damage |
EP2357477B1 (en) | 2003-09-20 | 2017-11-08 | Electrophoretics Limited | Diagnostic method for brain damage-related disorders based on the detection of NDKA |
GB0322063D0 (en) * | 2003-09-20 | 2003-10-22 | Univ Geneve | Diagnostic method for brain damage-related disorders |
EP1519194A1 (en) * | 2003-09-24 | 2005-03-30 | Roche Diagnostics GmbH | Use of gfap for identification of intracerebral hemorrhage |
EP2207033B1 (en) * | 2004-04-15 | 2014-06-18 | University of Florida Research Foundation, Inc. | Neural proteins as biomarkers for nervous system injury and other neural disorders |
ES2367311T3 (es) * | 2004-04-15 | 2011-11-02 | University Of Florida Research Foundation, Inc. | Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales. |
EP3115785A3 (en) | 2008-02-04 | 2017-02-22 | Banyan Biomarkers, Inc. | Process to diagnose or treat brain injury |
EP4235181A3 (en) * | 2008-08-11 | 2024-02-28 | Banyan Biomarkers Inc | Biomarker detection process and assay of neurological condition |
WO2018191531A1 (en) * | 2017-04-15 | 2018-10-18 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers |
BR112019022476A2 (pt) * | 2017-04-28 | 2020-05-12 | Abbott Laboratories | Métodos para o auxílio no diagnóstico e determinação hiperagudos de lesão cerebral traumática usando biomarcadores iniciais em pelo menos duas amostras a partir do mesmo ser humano |
BR112019025313A2 (pt) * | 2017-05-30 | 2020-06-23 | Abbott Laboratories | Métodos para auxílio no diagnóstico e avaliação de uma lesão cerebral traumática leve em um indivíduo humano usando troponina cardíaca i |
US11016105B2 (en) * | 2017-12-09 | 2021-05-25 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1 |
EP3721233A2 (en) * | 2017-12-09 | 2020-10-14 | Abbott Laboratories | Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1) |
-
2009
- 2009-08-11 EP EP23168587.6A patent/EP4235181A3/en active Pending
- 2009-08-11 ES ES09807153.3T patent/ES2665245T3/es active Active
- 2009-08-11 AU AU2009282117A patent/AU2009282117B2/en active Active
- 2009-08-11 DK DK09807153.3T patent/DK2324360T3/en active
- 2009-08-11 NO NO09807153A patent/NO2324360T3/no unknown
- 2009-08-11 EP EP09807153.3A patent/EP2324360B1/en not_active Revoked
- 2009-08-11 WO PCT/US2009/053376 patent/WO2010019553A2/en active Application Filing
- 2009-08-11 CA CA2733990A patent/CA2733990C/en active Active
- 2009-08-11 EP EP18154197.0A patent/EP3336551B1/en active Active
- 2009-08-11 US US13/058,748 patent/US20110143375A1/en not_active Abandoned
- 2009-08-11 JP JP2011523089A patent/JP5781436B2/ja active Active
-
2014
- 2014-07-24 JP JP2014150903A patent/JP5976732B2/ja active Active
-
2017
- 2017-09-19 US US15/709,368 patent/US20180031577A1/en not_active Abandoned
-
2020
- 2020-06-02 US US16/890,943 patent/US20210011028A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2665245T3 (es) | 2018-04-25 |
AU2009282117B2 (en) | 2016-05-12 |
US20210011028A1 (en) | 2021-01-14 |
EP2324360A2 (en) | 2011-05-25 |
EP2324360A4 (en) | 2012-08-29 |
US20180031577A1 (en) | 2018-02-01 |
WO2010019553A2 (en) | 2010-02-18 |
JP2014199262A (ja) | 2014-10-23 |
EP4235181A2 (en) | 2023-08-30 |
US20110143375A1 (en) | 2011-06-16 |
DK2324360T3 (en) | 2018-05-14 |
AU2009282117A1 (en) | 2010-02-18 |
EP2324360B1 (en) | 2018-01-31 |
JP5976732B2 (ja) | 2016-08-24 |
JP5781436B2 (ja) | 2015-09-24 |
CA2733990C (en) | 2018-12-11 |
WO2010019553A3 (en) | 2010-07-08 |
EP3336551B1 (en) | 2023-05-31 |
EP4235181A3 (en) | 2024-02-28 |
CA2733990A1 (en) | 2010-02-18 |
EP3336551A1 (en) | 2018-06-20 |
JP2012500388A (ja) | 2012-01-05 |